ReviewCurrent opinion in biotechnology2026
Advances in artificial biosynthesis of bioactive plant natural products.
Review in Current opinion in biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Plant natural products (PNPs) offer exceptional chemical diversity and therapeutic potential, but their low natural abundance and complex biosynthetic origins often hinder scalable access. Microbial heterologous reconstruction has enabled the production of select PNPs, yet major challenges remain, including incomplete pathway elucidation, limited enzyme performance, and poor metabolic compatibility. Emerging advances in artificial biosynthesis provide a complementary strategy to transcend the constraints of native plant metabolism. By leveraging enzyme promiscuity, precursor prefunctionalization, modular pathway design, and recruitment of repurposed or engineered catalysts, artificial biosynthesis enables streamlined, controllable, and evolvable routes to structurally complex PNP scaffolds. These innovations define a rapidly advancing paradigm in which PNPs can be biosynthesized through predictive, design-driven, and non-natural pathways, offering new opportunities for discovery and sustainable biomanufacturing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.